Adamis rises as safety panel allows COVID-19 treatment study

DMK Pharmaceuticals

01/06/2022 13:34

** Shares of biopharmaceutical co Adamis Pharmaceuticals
Corp  ADMP.O  rise 4.1% to 50 cents premarket
    ** Co says Data Safety Monitoring Board has determined that
ADMP's mid-to-late stage trial testing oral antiviral drug
Tempol in COVID-19 patients can continue as planned  urn:newsml:reuters.com:*:nFWN2XO076
    ** Decision made after evaluation of trial's interim
clinical and safety data 
    ** Co has worldwide license to use Tempol to treat
respiratory diseases including asthma and influenza
    ** Stock has lost ~20% YTD, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))